Comparison of the prognostic utility of the revised International Prognostic Scoring System and the French Prognostic Scoring System in azacitidine-treated patients with myelodysplastic syndromes Academic Article uri icon


MeSH Major

  • Antimetabolites, Antineoplastic
  • Azacitidine
  • Myelodysplastic Syndromes


  • The revised International Prognostic Scoring System (IPSS-R) was developed in a cohort of untreated myelodysplastic syndromes (MDS) patients. A French Prognostic Scoring System (FPSS) was recently reported to identify differential survival among azacitidine-treated patients with high-risk MDS. We applied the FPSS and IPSS-R to 150 patients previously randomized to azacitidine monotherapy or a combination of azacitidine with entinostat (a histone deacetylase inhibitor). Neither score predicted response but both discriminated patients with different overall survival (OS; median OS, FPSS: 9·7, 14·7, and 25·3 months, P = 0·018; IPSS-R: 12·5, 11·3, 20·8, and 36 months, P = 0·005). Statistical analysis suggested no improvement in OS prediction for the FPSS over the IPSS-R in azacitidine-treated patients.

publication date

  • January 2014



  • Academic Article



  • eng

PubMed Central ID

  • PMC4299460

Digital Object Identifier (DOI)

  • 10.1111/bjh.12884

PubMed ID

  • 24712482

Additional Document Info

start page

  • 352

end page

  • 9


  • 166


  • 3